Abstract:Objective: Antibody-drug conjugates (ADCs) that target human epidermal growth factor receptor 2 (HER2) are leading a new era of targeted cancer therapy. These drugs have also been associated with several fatal adverse events, such as pneumonia, interstitial lung disease, and infection. We performed a meta-analysis of randomized controlled trials (RCTs) to estimate the incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted ADCs. Methods: We performed a systematic search in Embase, PubMed, Web of Science, and Scopus databases from inception to February 1, 2022, and the last search was updated to July 1, 2023. The eligible studies for inclusion in our analysis were limited to RCTs of HER2-targeted ADCs that were approved by the US Food and Drug Administration and examined on cancer patients with available data on fatal adverse events. The protocol for this study was registered in PROSPERO (No. CRD42022331627). Results: Fifteen studies (13 RCTs) involving 7,277 patients were finally included for meta-analysis. Of these patients, 4,246 received HER2-targeted ADCs and 3,481 received the control treatment. The data were combined using Bayesian hierarchical modeling, which allowed for the estimation of the mean incidence of fatal adverse events to be 0.78% (95% CrI: 0.28-1.37%, τ = 0.006) for the patients treated with HER2-targeted ADCs. The relative risk was 0.80 (95% CrI, 0.5-1.26, τ = 0.17) compared to control patients. Among 43 reported deaths caused by HER2-targeted ADCs, the most common fatal adverse event was respiratory toxicity, including pneumonia, pneumonitis, and interstitial lung disease. On subgroup analysis, no difference in the risk of fatal adverse events was found between different HER2-targeted ADCs or cancer types. Conclusion: Our findings suggest that the risk of fatal adverse events with HER2-targeted ADCs may be lower compared to standard control therapies in cancer patients, and there is no significant difference in risk observed between different HER2-targeted ADCs or cancer types. However, the most common fatal adverse event was respiratory toxicity, suggesting that cancer patients who use the above drugs should strengthen respiratory system monitoring and take preventive measures in some severe cases.

Lung toxicity induced by anti-HER2 antibody – drug conjugates for breast cancer

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Interstitial Lung Disease Associated with Anti-Her2 Anti-Body Drug Conjugates: Results from Clinical Trials and the WHO's Pharmacovigilance Database.

Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China

Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinical implications

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

A Narrative Review of Human Epidermal Growth Factor Receptor 2 (Her2)-Targeted Antibody-Drug Conjugates in the Treatment of Breast Cancer

HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges

Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment

[Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression]

Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system

The Efficacy of Ado-Trastuzumab Emtansine in Patients with HER-2-aberrant Non-Small Cell Lung Cancer.

T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives

High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database